Evaluating the role of gross total resection in primary spinal cord glioblastoma: evidence from a multicenter cohort and meta-analysis.

IF 3.1 2区 医学 Q2 CLINICAL NEUROLOGY
Journal of Neuro-Oncology Pub Date : 2025-11-01 Epub Date: 2025-07-16 DOI:10.1007/s11060-025-05158-y
Giuseppe Corazzelli, Sergio Corvino, Luigi Sigona, Valentina Cioffi, Francesco Ricciardi, Maria Rosaria Scala, Cristina Mancarella, Ciro Mastantuoni, Anthony Kevin Scafa, Francesco de Falco, Valentina Pizzuti, Alessandro D'Elia, Settimio Leonetti, Salvatore Di Colandrea, Giuseppe Catapano, Antonio Bocchetti, Sergio Paolini, Vincenzo Esposito, Gualtiero Innocenzi, Raffaele de Falco
{"title":"Evaluating the role of gross total resection in primary spinal cord glioblastoma: evidence from a multicenter cohort and meta-analysis.","authors":"Giuseppe Corazzelli, Sergio Corvino, Luigi Sigona, Valentina Cioffi, Francesco Ricciardi, Maria Rosaria Scala, Cristina Mancarella, Ciro Mastantuoni, Anthony Kevin Scafa, Francesco de Falco, Valentina Pizzuti, Alessandro D'Elia, Settimio Leonetti, Salvatore Di Colandrea, Giuseppe Catapano, Antonio Bocchetti, Sergio Paolini, Vincenzo Esposito, Gualtiero Innocenzi, Raffaele de Falco","doi":"10.1007/s11060-025-05158-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Primary spinal cord glioblastoma (PscGB) is a rare, aggressive tumor that accounts for about 7.5% of spinal cord gliomas. Its infiltrative growth and proximity to critical neural structures make diagnosis and management challenging, and data on prognostic factors and optimal treatment remain limited.</p><p><strong>Objective: </strong>To evaluate the impact of the extent of surgical resection and adjuvant chemoradiotherapy on overall survival (OS) in PscGB, and to identify independent predictors of poor prognosis.</p><p><strong>Methods: </strong>A retrospective multicenter cohort was analyzed alongside a systematic review and meta-analysis of comparative clinical studies. Through stringent enrollment criteria, demographic, clinical, radiological, and surgical data were collected. The overall survival (OS) was the primary outcome. Survival outcomes were evaluated with Kaplan-Meier curves, while predictors of better OS were identified using univariate and multivariate least squares regression. For the meta-analysis, individual patient data were retrieved where available, and a random-effects model using hazard ratios (HR) assessed the effects of extent of resection and adjuvant therapy on survival.</p><p><strong>Results: </strong>The multicenter cohort (n = 13) and systematic review (n = 67) together included 80 operated PscGB patients. The meta-analysis combined data from five published comparative studies plus our institutional series, for a total of 111 patients. No significant difference in OS was observed among patients undergoing gross total resection, subtotal resection, or biopsy (HR = 0.68, 95% CI: 0.29-1.58; p = 0.37). In contrast, adjuvant chemoradiotherapy was significantly associated with improved survival (HR = 0.37, 95% CI: 0.17-0.78; p = 0.009). Multivariate analysis identified delayed surgery (p < 0.01) and absence of adjuvant chemoradiotherapy (p < 0.01) as independent predictors of poorer OS. Sensitivity and publication bias analyses supported the robustness of these findings.</p><p><strong>Conclusion: </strong>In this study, gross total resection did not provide a significant survival benefit in PscGB, while earlier surgery and adjuvant chemoradiotherapy were associated with improved outcomes. However, our findings are to be interpreted as merely observational and not conclusive and therefore should be observed with caution. Larger prospective studies are needed to confirm these results and inform clinical practice.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"633-645"},"PeriodicalIF":3.1000,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuro-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11060-025-05158-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/16 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Primary spinal cord glioblastoma (PscGB) is a rare, aggressive tumor that accounts for about 7.5% of spinal cord gliomas. Its infiltrative growth and proximity to critical neural structures make diagnosis and management challenging, and data on prognostic factors and optimal treatment remain limited.

Objective: To evaluate the impact of the extent of surgical resection and adjuvant chemoradiotherapy on overall survival (OS) in PscGB, and to identify independent predictors of poor prognosis.

Methods: A retrospective multicenter cohort was analyzed alongside a systematic review and meta-analysis of comparative clinical studies. Through stringent enrollment criteria, demographic, clinical, radiological, and surgical data were collected. The overall survival (OS) was the primary outcome. Survival outcomes were evaluated with Kaplan-Meier curves, while predictors of better OS were identified using univariate and multivariate least squares regression. For the meta-analysis, individual patient data were retrieved where available, and a random-effects model using hazard ratios (HR) assessed the effects of extent of resection and adjuvant therapy on survival.

Results: The multicenter cohort (n = 13) and systematic review (n = 67) together included 80 operated PscGB patients. The meta-analysis combined data from five published comparative studies plus our institutional series, for a total of 111 patients. No significant difference in OS was observed among patients undergoing gross total resection, subtotal resection, or biopsy (HR = 0.68, 95% CI: 0.29-1.58; p = 0.37). In contrast, adjuvant chemoradiotherapy was significantly associated with improved survival (HR = 0.37, 95% CI: 0.17-0.78; p = 0.009). Multivariate analysis identified delayed surgery (p < 0.01) and absence of adjuvant chemoradiotherapy (p < 0.01) as independent predictors of poorer OS. Sensitivity and publication bias analyses supported the robustness of these findings.

Conclusion: In this study, gross total resection did not provide a significant survival benefit in PscGB, while earlier surgery and adjuvant chemoradiotherapy were associated with improved outcomes. However, our findings are to be interpreted as merely observational and not conclusive and therefore should be observed with caution. Larger prospective studies are needed to confirm these results and inform clinical practice.

评估原发性脊髓胶质母细胞瘤总切除的作用:来自多中心队列和荟萃分析的证据。
背景:原发性脊髓胶质母细胞瘤(PscGB)是一种罕见的侵袭性肿瘤,约占脊髓胶质瘤的7.5%。其浸润性生长和靠近关键神经结构使得诊断和管理具有挑战性,并且预后因素和最佳治疗的数据仍然有限。目的:评价手术切除范围及辅助放化疗对PscGB患者总生存期(OS)的影响,寻找预后不良的独立预测因素。方法:对回顾性多中心队列进行分析,并对比较临床研究进行系统回顾和荟萃分析。通过严格的入组标准,收集了人口统计学、临床、放射学和外科数据。总生存期(OS)是主要终点。使用Kaplan-Meier曲线评估生存结果,而使用单变量和多变量最小二乘回归确定更好的OS的预测因子。在荟萃分析中,检索了可用的个体患者数据,并使用风险比(HR)的随机效应模型评估了切除程度和辅助治疗对生存的影响。结果:多中心队列(n = 13)和系统评价(n = 67)共纳入80例手术后PscGB患者。荟萃分析结合了来自五项已发表的比较研究和我们的机构系列的数据,共111名患者。接受大体全切除、次全切除或活检的患者OS无显著差异(HR = 0.68, 95% CI: 0.29-1.58;p = 0.37)。相比之下,辅助放化疗与生存率的提高显著相关(HR = 0.37, 95% CI: 0.17-0.78;p = 0.009)。多变量分析确定延迟手术(p)结论:在本研究中,PscGB的总切除并没有提供显著的生存益处,而早期手术和辅助放化疗与改善预后相关。然而,我们的发现仅仅是观察性的,而不是结论性的,因此应该谨慎观察。需要更大规模的前瞻性研究来证实这些结果并为临床实践提供信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Neuro-Oncology
Journal of Neuro-Oncology 医学-临床神经学
CiteScore
6.60
自引率
7.70%
发文量
277
审稿时长
3.3 months
期刊介绍: The Journal of Neuro-Oncology is a multi-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neurodiagnosticians, and laboratory-based oncologists conducting relevant research. The Journal of Neuro-Oncology does not seek to isolate the field, but rather to focus the efforts of many disciplines in one publication through a format which pulls together these diverse interests. More than any other field of oncology, cancer of the central nervous system requires multi-disciplinary approaches. To alleviate having to scan dozens of journals of cell biology, pathology, laboratory and clinical endeavours, JNO is a periodical in which current, high-quality, relevant research in all aspects of neuro-oncology may be found.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信